News

FDA Approves Carfilzomib for Once-Weekly Dosing Regimen in Multiple Myeloma

Officials with the FDA have approved a supplemental New Drug Application (sNDA) to expand the use of carfilzomib (Kyprolis, Amgen) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. “The availability of a more convenient once-weekly dosing regimen, with superior efficacy, comparable safety and longer duration of therapy versus the twice-weekly regimen studied in the trial could allow patients to spend more time outside of the infusion center,” David S. Siegel, M.D., Ph.D, chief of the Division of Multiple Myeloma at John Theurer Cancer Center. (This announcement was also featured on Healio, Market Watch, and SPT Industry Guide.)

READ FULL ARTICLE ON SPECIALTYRXACCESS.COM